Tags : Therachon

Pfizer to Acquire Therachon for the Expansion of its Rare

Shots: Pfizer acquires Therachon, in all stock transaction for $810M. Therachon to receive $340M upfront with additional payment on milestones of development and commercialization of its  TA-46 candidate targeted for achondroplasia Additionally, Therachon to spin-off its apraglutide development program into an independent firm, prior closure of the transaction. Pfizer Ventures to hold an equity stake […]Read More

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Shots: Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with $60M The focus of the agreement is to improve QoL by providing novel and efficacious therapies for rare conditions including short bowel syndrome(SBS) and rare […]Read More